CSL Ltd
AUAUDCSL Ltd (US:CMXHF) — Biotechnology. Antal børser, hvor selskabets aktier handles: 2. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.
Om Virksomheden
- Websted
- csl.com.au
- Investorrelationer
- investors.csl.com/
- Sektor
- Healthcare · Biotechnology
- Hovedkontor
- Melbourne, Australia
- Administrerende Direktør
- Gordon Naylor BEng
- Ansatte
- 29 000
- Grundlagt
- 1994
- Udestående Aktier
- 479.88 mio.
- Free Float
- 478.53 mio.
- Markedsværdi
- 87.08 mia. AUD
- Insidere
- 0.02%
- Institutionelle Investorer
- 38.27%
- Juridisk Form
- R4KK
- ISIN
- AU000000CSL8
- LEI
- 529900ECSECK5ZDQTE14
- P/E
- underskud
- P/B
- 4.38
- Udbetalingsgrad
- underskud
- FCF
- 2.23 mia. USD
- Udbetaling / FCF
- 70%
- Gæld
- 10.9 mia. USD3.5 år FCF
- Udbyttestreak
- 31 år
- Indtjening, FCF og udbetalt udbytte — for de 12 måneder frem til 30.06.2026 (selskabets seneste rapport).
- NAV
Beskrivelse
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants. The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments. The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology. The company's therapeutic areas includes Immunoglobulins, Immunology, Immunology Haematology, Cardiovascular and Renal, and Vaccines. It also licenses CSL intellectual property. It also develops vaccines for the prevention of infectious disease. The company has strategic collaboration with Dutch biotech company VarmX BV for the development of VMX-C001 to help restore blood coagulation in patients requiring urgent surgery; and Alentis Therapeutics AG to develop and commercialise lixudebart for rare kidney and liver diseases. The company was formerly known as Commonwealth Serum Laboratories Limited and later changed its name to CSL Limited in October 1991. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
Udbytte
CSL Ltd (CSL) udbetaler udbytte to gange om året. Pr. År (12 måneder op til og med den senest annoncerede betaling): 4.0536 AUD pr. Aktie (betalinger: 2). Det svarer til cirka 2.06% af den nuværende aktiekurs. Baseret på betalingshistorikken forventes næste ex-udbyttedato omkring 10.03.2027. Uafbrudt udbyttehistorik: 31 år.
| Ex-Dato | Udbetaling | Beløb | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-09-09 | — | 2.2438 AUD | 1.3/2.3 % | halvårlig | AU:CSL |
| 2026-03-10 | — | 1.8098 AUD | 1.3/3.0 % | halvårlig | AU:CSL |
| 2025-09-09 | — | 2.4508 AUD | 1.1/2.1 % | halvårlig | AU:CSL |
| 2025-03-10 | — | 2.0727 AUD | 0.8/1.6 % | halvårlig | AU:CSL |
| 2024-09-09 | — | 2.1746 AUD | 0.7/1.3 % | halvårlig | AU:CSL |
| 2024-03-11 | — | 1.7989 AUD | 0.6/1.3 % | halvårlig | AU:CSL |
| 2023-09-11 | — | 2.0078 AUD | 0.7/1.3 % | halvårlig | AU:CSL |
| 2023-03-09 | — | 1.6215 AUD | 0.5/1.1 % | halvårlig | AU:CSL |
| 2022-09-06 | — | 1.7583 AUD | 0.6/1.1 % | halvårlig | AU:CSL |
| 2022-03-07 | — | 1.4229 AUD | 0.6/0.6 % | halvårlig | AU:CSL |
Største Ejere
| Ejer | Andel | Aktier | Rapportdato |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.49% | 7.16 mio. | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.99% | 4.75 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 0.75% | 3.6 mio. | 2026-08-31 |
| Fidelity Concord Street… | 0.39% | 1.89 mio. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.36% | 1.72 mio. | 2026-08-31 |
| J.P. Morgan Exch-Trd Fd.… | 0.3% | 1.45 mio. | 2026-07-31 |
| Fidelity Salem Street TR… | 0.29% | 1.38 mio. | 2026-07-31 |
| iShares Trust-iShares MS… | 0.28% | 1.35 mio. | 2026-08-31 |
| VANGUARD Intl Eqy. INDEX… | 0.24% | 1.16 mio. | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 0.22% | 1.08 mio. | 2026-05-31 |
| Pacer Advisors, Inc. | 0.08% | 369 774 | 2026-06-30 |
| Naylor (Gordon) (Directo… | ≈0.01% | 40 819 | 2026-05-26 |
| McKenzie (Paul F) (Chief… | ≈0.01% | 31 053 | 2025-09-01 |
| McNamee (Brian Anthony)… | ≈0.01% | 30 561 | 2026-08-21 |
| Linton (Joy) (Chief Fina… | ≈0% | 15 096 | 2025-06-30 |
| Watkins (Alison Mary) (I… | ≈0% | 6 989 | 2026-08-21 |
| Clark (Megan Elizabeth)… | ≈0% | 5 718 | 2025-08-22 |
| Schmeltz (Andy) (Other E… | ≈0% | 5 067 | 2025-06-30 |
| Hewson (Carolyn Judith)… | ≈0% | 4 131 | 2026-08-21 |
| Price (Cameron Bruce) (I… | ≈0% | 3 559 | 2026-08-21 |
| Daniels (Brian M.D.) (No… | ≈0% | 3 400 | 2025-11-18 |
